What happens when you stop taking tirzepatide?

Does weight come back after you stop tirzepatide?

The honest answer is: for most people, yes, and the evidence is clear on this. Tirzepatide works by activating GIP and GLP-1 receptors that regulate appetite signals and the speed at which the stomach empties. While you are taking it, those signals are consistently modulated. Stop the injections, and within a few weeks the drug is no longer active in your body, those signals return to baseline, and hunger typically rebounds to pre-treatment levels.

Data from the SURMOUNT programme (which enrolled thousands of adults across its trials) showed that participants who discontinued tirzepatide regained a substantial proportion of the weight they had lost, with most of the regain occurring in the 12 months following the final injection. This pattern is not unique to tirzepatide; it is seen across GLP-1 class medicines. The SURMOUNT-1 trial, published in the New England Journal of Medicine, provides the foundational data on what participants achieved while on treatment, the contrast with what happens after stopping is striking.

One misconception worth setting aside gently: that weight returning after stopping means the medicine never really worked. It did work, and precisely because it worked by altering an ongoing physiological process rather than correcting a permanent deficiency, the effect is tied to continued use. Understanding that framing can change how you approach the decision to stop.

For a fuller picture of what happens when you stop using Mounjaro, from the first week through to the months that follow your last injection, our dedicated page covers the practical side in more detail.

What actually happens in your body in the weeks after your last injection?

Tirzepatide has a half-life of around five days, meaning it takes roughly three to four weeks to clear fully after your last dose. During that window, you may notice a gradual shift rather than an abrupt change, appetite beginning to increase, food feeling less filling, the strong satiety signals that made smaller portions feel sufficient starting to loosen.

Gastric emptying, which tirzepatide slows, will return to its usual pace. For some people this means meals move through more quickly again, which can reduce the feeling of fullness after eating. Blood sugar regulation, if that was part of why tirzepatide was prescribed alongside weight management, may also shift, another reason to keep your prescriber involved.

Side effects that were present during treatment (particularly any lingering gastrointestinal symptoms) typically resolve as the drug clears. Most people find the weeks immediately after stopping feel physically relatively unremarkable; the hunger change builds gradually rather than arriving overnight.

If you are curious about how tirzepatide acts when you are on it, that context makes the reversal easier to understand. The Mounjaro injection page covers the practical mechanics of the treatment itself.

Are there situations where stopping tirzepatide is the right call?

Yes, and they vary considerably. Some people stop because treatment goals have been met and they want to trial maintenance without medication. Others stop for medical reasons: a planned surgical procedure (the NHS advises telling your anaesthetist and surgical team that you are taking a GLP-1 medicine before any operation), pregnancy planning (tirzepatide is not recommended in pregnancy, while breastfeeding, or when actively trying to conceive), or a newly diagnosed condition that changes the clinical picture.

Supply interruptions have also led some people to stop tirzepatide without planning to, which is a different situation entirely. If a gap in supply is the issue, your prescriber can advise on how to restart safely. Restarting after a longer break may mean returning to a lower dose to manage tolerability.

Cost is a factor for some people. If you want to understand what tirzepatide costs as a private prescription, that page sets out what an all-in price should include, consultation, clinical review, delivery. Stopping purely on cost grounds is worth discussing with your prescriber first; there may be options.

NICE's appraisal of tirzepatide (TA1026) notes that continuing beyond six months at the highest tolerated dose should be reviewed if less than 5% weight loss has been achieved. That is a clinical threshold that belongs in a conversation with your prescriber, not a reason to stop unilaterally.

What should you do if you are thinking about stopping tirzepatide?

Talk to your prescriber before making the change, where possible. This is not a bureaucratic hurdle, it is genuinely useful. A prescriber can help you think through whether a planned pause is the right move, what to expect physically, whether a structured wind-down or a clean stop makes more sense given your situation, and what to put in place to support whatever comes next.

If weight management remains a goal after stopping, the evidence points clearly to sustained lifestyle changes being the main factor that slows regain. Some people later return to tirzepatide; the medicine remains a licensed option for adults with a BMI of 30 or above (or 27 with a relevant health condition), and restarting is possible after clinical reassessment.

Our weight-loss treatment overview covers the broader landscape of options, and you can read about stopping Mounjaro from a patient perspective on that page. If your question is about a specific clinical situation (a procedure, pregnancy planning, or a condition that has changed) reaching out to our team is the clearest route to an accurate answer for your circumstances. Speak to our prescribers through a free consultation if you are weighing up what stopping means for you.